Abstract
Ifosfamide (5 g/m2) was compared with its parent analogue cyclophosphamide (1.5 g/m2) in a randomized phase II study. Both drugs were given by 24-h intravenous (i.v.) infusion every 3 weeks along with i.v. bolus infusions of mesna (400 mg/m2), which was given every 4 h for nine administrations. Eligibility criteria included an age of 15-75 years, biopsy-proven advanced metastatic soft-tissue sarcoma, and a World Health Organization performance status of 0-2. Exclusion criteria were prior treatment with classic alkylating agents, a creatinine level of >150 μmol/l, a bilirubin level of >20 μmol/l, a leukocyte cell count of 9/l, and a platelet count of 9/l. A total of 171 patients were entered, 24 of whom were ineligible and 12, inevaluable, leaving 135 patients evaluable. In all, 67 patients were treated with cyclophosphamide, and the overall response rate was 7.5%. All responders to cyclophosphamide were patients who had not received prior chemotherapy (13% of 38 patients). Another 68 patients were given ifosfamide, 18% of whom responded to treatment. Of the 28 ifosfamide-treated patients who had received prior chemotherapy, 7% were responders. The response rate for the remaining 40 patients was 25%. The higher overall response rate (P = 0.13) obtained with less myelosuppression in ifosfamide-treated patients suggests that this agent may have advantages over cyclophosphamide in combination therapy.
| Original language | English |
|---|---|
| Journal | Cancer Chemotherapy and Pharmacology |
| Volume | 31 |
| Issue number | SUPPL. 2 |
| Publication status | Published - 1993 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
- Pharmacology
Cite this
Cyclophosphamide versus ifosfamide : A randomized phase II trial in adult soft-tissue sarcomas. / Bramwell, V. H C; Mouridsen, H. T.; Santoro, A.; Blackledge, G.; Somers, R.; Verweij, J.; Dombernowsky, P.; Onsrud, M.; Thomas, D.; Sylvester, R.; Van Oosterom, A.
In: Cancer Chemotherapy and Pharmacology, Vol. 31, No. SUPPL. 2, 1993.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cyclophosphamide versus ifosfamide
T2 - A randomized phase II trial in adult soft-tissue sarcomas
AU - Bramwell, V. H C
AU - Mouridsen, H. T.
AU - Santoro, A.
AU - Blackledge, G.
AU - Somers, R.
AU - Verweij, J.
AU - Dombernowsky, P.
AU - Onsrud, M.
AU - Thomas, D.
AU - Sylvester, R.
AU - Van Oosterom, A.
PY - 1993
Y1 - 1993
N2 - Ifosfamide (5 g/m2) was compared with its parent analogue cyclophosphamide (1.5 g/m2) in a randomized phase II study. Both drugs were given by 24-h intravenous (i.v.) infusion every 3 weeks along with i.v. bolus infusions of mesna (400 mg/m2), which was given every 4 h for nine administrations. Eligibility criteria included an age of 15-75 years, biopsy-proven advanced metastatic soft-tissue sarcoma, and a World Health Organization performance status of 0-2. Exclusion criteria were prior treatment with classic alkylating agents, a creatinine level of >150 μmol/l, a bilirubin level of >20 μmol/l, a leukocyte cell count of 9/l, and a platelet count of 9/l. A total of 171 patients were entered, 24 of whom were ineligible and 12, inevaluable, leaving 135 patients evaluable. In all, 67 patients were treated with cyclophosphamide, and the overall response rate was 7.5%. All responders to cyclophosphamide were patients who had not received prior chemotherapy (13% of 38 patients). Another 68 patients were given ifosfamide, 18% of whom responded to treatment. Of the 28 ifosfamide-treated patients who had received prior chemotherapy, 7% were responders. The response rate for the remaining 40 patients was 25%. The higher overall response rate (P = 0.13) obtained with less myelosuppression in ifosfamide-treated patients suggests that this agent may have advantages over cyclophosphamide in combination therapy.
AB - Ifosfamide (5 g/m2) was compared with its parent analogue cyclophosphamide (1.5 g/m2) in a randomized phase II study. Both drugs were given by 24-h intravenous (i.v.) infusion every 3 weeks along with i.v. bolus infusions of mesna (400 mg/m2), which was given every 4 h for nine administrations. Eligibility criteria included an age of 15-75 years, biopsy-proven advanced metastatic soft-tissue sarcoma, and a World Health Organization performance status of 0-2. Exclusion criteria were prior treatment with classic alkylating agents, a creatinine level of >150 μmol/l, a bilirubin level of >20 μmol/l, a leukocyte cell count of 9/l, and a platelet count of 9/l. A total of 171 patients were entered, 24 of whom were ineligible and 12, inevaluable, leaving 135 patients evaluable. In all, 67 patients were treated with cyclophosphamide, and the overall response rate was 7.5%. All responders to cyclophosphamide were patients who had not received prior chemotherapy (13% of 38 patients). Another 68 patients were given ifosfamide, 18% of whom responded to treatment. Of the 28 ifosfamide-treated patients who had received prior chemotherapy, 7% were responders. The response rate for the remaining 40 patients was 25%. The higher overall response rate (P = 0.13) obtained with less myelosuppression in ifosfamide-treated patients suggests that this agent may have advantages over cyclophosphamide in combination therapy.
UR - http://www.scopus.com/inward/record.url?scp=0027533415&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027533415&partnerID=8YFLogxK
M3 - Article
C2 - 8453694
AN - SCOPUS:0027533415
VL - 31
JO - Cancer Chemotherapy and Pharmacology
JF - Cancer Chemotherapy and Pharmacology
SN - 0344-5704
IS - SUPPL. 2
ER -